

NCIC CLINICAL TRIALS GROUP

**ADVANCED BLADDER, TESTES AND KIDNEY**

GU DISEASE ORIENTED GROUP MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO, ON

*ROOM: WREN*

SATURDAY APR 27<sup>TH</sup>, 2013, 7:30 AM – 9:00 AM

CO-CHAIRS : S. NORTH, W. KASSOUF, J. KNOX, A. KAPOOR, C. KOLLMANNBERGER & P. CHUNG

**CME Credits:**

*Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen's University.*

**Learning Objectives:**

- *To understand and address, through clinical and translational research, the disease burden associated with genitourinary malignancies (renal, bladder and testicular cancer) in Canada.*
  - *To review recent developments in the understanding of molecular biology and new therapeutics as these relate to genitourinary malignancies.*
  - *To update, review, and discuss recent results of clinical studies conducted by the NCIC Clinical Trials Group and/or by national/ international collaborators.*
  - *To provide a learning environment supportive to new investigators.*
  - *To understand and apply new clinical trial methodologies in the field of clinical research related to genitourinary malignancies.*
- 

**7:30 am**      **Welcome**

***Ongoing Studies Updates***

**7:35 am**      Personalised Sunutinib dosing in mRCC      **G. Bjarnason**

**7:40 am**      EORTC cytoreductive nephrectomy (SURTIME)      **M. Jewett**

**7:45 am**      International mRCC Database Consortium      **D. Heng**

***Update on NCIC CTG Approved Studies***

**7:50 am**      A Phase II Randomized trial of Nab-Paclitaxel vs. Paclitaxel in Second Line Metastatic Urothelial Carcinoma      **K. Sridhar**

*continued on next page ...*

### ***Study Proposals***

- |                |   |                  |
|----------------|---|------------------|
| <b>8:10 am</b> | Stereotactic radiotherapy for oligo-progression of metastatic kidney cancer patients on 1 <sup>st</sup> line targeted therapy: phase II | <b>P. Cheung</b> |
| <b>8:35 am</b> | Adjuvant RT in Muscle Invasive Bladder Cancer Treated with Cystectomy   | <b>L. Eapen</b>  |
| <b>9:00 am</b> | <b>Meeting Adjourned</b>  |                  |